| Source: |
Escherichia coli |
| Molecular Weight: |
Approximately 33.8 kDa, a single non-glycosylated polypeptide chain containing 306 amino acids. |
| AA Sequence: |
SGFRKMAFPS GKVEGCMVQV TCGTTTLNGL WLDDVVYCPR HVICTSEDML NPNYEDLLIR KSNHNFLVQA GNVQLRVIGH SMQNCVLKLK VDTANPKTPK YKFVRIQPGQ TFSVLACYNG SPSGVYQCAM RPNFTIKGSF LNGSCGSVGF NIDYDCVSFC YMHHMELPTG VHAGTDLEGN FYGPFVDRQT AQAAGTDTTI TVNVLAWLYA AVINGDRWFL NRFTTTLNDF NLVAMKYNYE PLTQDHVDIL GPLSAQTGIA VLDMCASLKE LLQNGMNGRT ILGSALLEDE FTPFDVVRQC SGVTFQ |
| Purity: |
> 97% by SDS-PAGE. |
| Physical Appearance: |
White lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH7.0, with 5% trehalose, 0.02% Tween-20. |
| Endotoxin: |
Less than 0.1 EU/μg of rSARS-CoV-2 3CL Protease as determined by LAL method. |
| Reconstitution: |
We recommend that this vial is briefly centrifuged prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Background: |
The 3CL protease (also known as 3CLpro, Mpro, or "Main" Protease) from the human SARS-CoV-2 coronavirus is a C30-type cysteine protease. The activity of 3CLpro is essential for processing the viral polyprotein into functional, mature subunits, involving cleavage at over 11 sites, many of which contain the sequence LQ[S/A/G]. This protease cleaves at the C-terminal of the glutamine amino acid. Along with the CoV-2 Papain-Like Protease, 3CLpro is a promising target for COVID-19 therapeutic interventions. Since no human proteases with similar cleavage specificity are known, inhibitors of 3CLpro are unlikely to cause mechanism-based toxicity. |
